期刊文献+

吡格列酮对不同浓度脂肪酸培养HepG2细胞脂联素受体1和受体2mRNA表达的影响 被引量:1

The effect of pioglitazone on the adiponectin receptor expression of fatty acids-treated HepG2 cell
下载PDF
导出
摘要 目的探讨肝细胞脂联素受体在噻唑烷二酮类药物改善胰岛素敏感性中所起的作用。方法孵育48h的HepG2细胞随机均分为对照组、吡格列酮组、3组不同浓度(100、200、400μmol/L)饱和脂肪酸(PA)培养组和3组相应浓度PA+吡格列酮(PGT)处理组。继续培养24h后,提取总RNA,使用RTPCR半定量分析脂联素受体mRNA表达的改变。结果与对照组相比,PA组脂联素受体2(R2)mRNA的表达下降,当PA的浓度加至200μmol/L以上时,R2mRNA表达的下降呈现明显差异(P<0.01)。在PA+PGT的各组中,R2mRNA的表达均较同PA浓度组增高,尤其是在PA浓度大于200μmol/L时(P<0.05或P<0.01)。结论R2很可能是胰岛素增敏剂吡格列酮改善肝脏胰岛素敏感性的重要作用机制之一。 Objective To investigate the effect of pioglitazone(PGT) on the adiponectin receptor expression of fatty acids-treated HepG2 cell. Methods HepG2 cells were cultivated and incubated for 48 hours, then randomly divided into 8 equivalent groups: control group, PGT group, 3 groups treated with 100,200 and 400 μmol/L of palmitic acid(PA) separately, and 3 groups treated with above concentrations of PA plus PGT 10 μmol/L(PA+PGT). Then the extracted total RNA were used for half-quantitative analysis of mRNA expression. Results The mRNA expressions of adiponectin receptor 2 (R2) were decreased in groups treated only with PA, especially in the groups over 200 μmol/L (P〈0.01). All the R2 mRNA were higher in PA+PGT groups than in corresponding PA groups, particularly in groups with PA above 200μmol/L(P〈0.05 or P〈0. 01). Conclusions The increased expression of R2 mRNA may play a important role in pioglitazone-induced insulin sensitivity amelioration.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2006年第3期218-220,共3页 Chinese Journal of Diabetes
基金 中央保健专项资金资助课题(解A064)
关键词 吡格列酮 脂肪酸 HEPG2细胞 脂联素受体 Pioglitazone Fatty acid HepG2 cell Adiponectin receptor
  • 相关文献

参考文献8

二级参考文献35

  • 1上海医学化验所主编.临床生化检验[M].上海:上海科技出版社,1979.168.
  • 2岸恭一 井上五郎.肥满动物模型[J].综合临床,1981,30(10):2452-9.
  • 3[1]Yoon JC, Chickering TW, Rosen ED, et al. Peroxisome proliferatoractivated receptor gamma target gene encoding a novel angiopoietinrelated protein associated with adipose differentiation. Mol Cell Biol, 2000,20(14): 5343.
  • 4[2]Hayakawa T, Shiraki T, Morimoto T, et al. Pioglitazone improves insulin signa liug defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem Biophys Res Commun, 1996, 223: 439.
  • 5[3]Fukui Y, Masui S, Osada S, et al. A new hiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes,2000,49(5): 759
  • 6[4]Paolisso G, Howard BV. Role of nonesterfiied fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabetic Med, 1998, 15: 360.
  • 7[5]Shimaya A, Kurosaki E, Nakano R, et al. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism,2000,49(3):411.
  • 8[6]De Vos P, Lefebvre AM, Miller SG, et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ.J Clin Invest, 1996, 98:1004.
  • 9[7]Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med, 2001,134(1):61.
  • 10[8]Grinsell JW, Lardinois CK,Swislocki A,et al. Pioglitazane attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens,2000,13(4 Pt 1): 370.

共引文献31

同被引文献1

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部